{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"28.7","upperLimit":"61.9","value":"40.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"102"}],"units":"Participants"}],"description":"Time from start of study treatment to date of death due to any cause.","dispersionType":"95% Confidence Interval","groups":[{"description":"Brentuximab vedotin 1.8 mg/kg every 3 weeks by IV infusion","id":"OG000","title":"Brentuximab Vedotin"}],"paramType":"MEDIAN","populationDescription":"Intention to treat","reportingStatus":"POSTED","timeFrame":"up to approximately 6 years","title":"Overall Survival","type":"SECONDARY","unitOfMeasure":"months"}